Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 11Gynecologic 5Thoracic 2Sarcoma 2Breast 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Lung Neoplasms 5Small Cell Lung Carcinoma 4Mesothelioma 3Neoplasms 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Urologic Neoplasms 1Stomach Neoplasms 1SCLC,Extensive Stage 1Recurrence 1Pancreatic Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × niraparib × Thoracic × Clear all
NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Tesaro, Inc.

Phase 1 Completed
60 enrolled 91 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03221400 2022-02-17

PEN-866 in Patients With Advanced Solid Malignancies

Tarveda Therapeutics

Phase 1/2 Unknown
340 enrolled
GastrointestinalThoracic

Anus Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡